reports
Royalty Pharma to Announce Third Quarter 2025 Financial Results on Nov...
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at to obtain conference call information and to view the live webcast. A replay of the confere...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Downgrading Financials to Underweight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. We would need to see a break below 6569 in order to have confidence that a consolidation period has finally begun. For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA. Short-term supports to buy include 6640 (the 20-day MA),...
TECH BIO-TECHNE CORPORATION
RGEN REPLIGEN CORPORATION
REGN REGENERON PHARMACEUTICALS INC.
GILD GILEAD SCIENCES INC.
EXEL EXELIXIS INC.
EXAS EXACT SCIENCES CORPORATION
ENS ENERSYS
BIIB BIOGEN INC.
BGNE BEIGENE LTD. SPONSORED ADR
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALNY ALNYLAM PHARMACEUTICALS INC
IONS IONIS PHARMACEUTICALS INC.
UTHR UNITED THERAPEUTICS CORPORATION
MDGL MADRIGAL PHARMACEUTICALS
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
QS QUANTUMSCAPE
ENVX ENOVIX CORP
FLNC FLUENCE ENERGY INC
SLDP SOLID POWER INC
MVST MICROVAST HLDGS INC
AMPX AMPRIUS TECHNOLOGIES INC
SES SES AI CORPORATION
ABAT AMERICAN BATTERY TECHNOLOGY COMPANY
TE ALUSSA ENERGY ACQUISITION CORP
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. “I am delighted to welcome Ted to the key role of Lead Independent Director,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. “Ted has extensive resea...
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the...
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Compa...
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensusGoal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma’s platform valueInvestments since 2020 on track to deliver mid-teens unlevered IRR, ahead of targetAchieved 15% Return on Invested Capital (ROIC) and 21% Return on Invested Equity (ROIE) since 2019Royalty market continues to ...
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma...
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansionRoyalties have become integral to biopharma’s diversified capital landscape driven by attractive cost of capital, flexibility and positive investor perception NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, ...
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Hea...
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a ...
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured N...
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 4.450% Notes due 2031 (the “2031 Notes”);$900 million of 5.200% Notes due 2035 (the “2035 Notes”); and$500 million of 5.950% Notes due 2055 (the “2055 Notes”). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, L...
Moody's Ratings assigns Baa2 rating to Royalty Pharma's new senior uns...
Moody's Ratings (Moody's) assigned Baa2 ratings to the new backed senior unsecured notes of Royalty Pharma plc ("Royalty Pharma"). There are no changes to Royalty Pharma's existing ratings including the Baa2 senior unsecured ratings. The outlook remains unchanged at stable. The proceeds from the o...
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agree...
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in fundi...
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up...
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by AmgenRoyalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additional portion of its royalty NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines ...
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. “We are tremendously grateful for Henry's contributions to Royalty Pharma over the past five years,” said Pablo Legorreta, founder and Chief Executive Officer o...
Royalty Pharma Reports Second Quarter 2025 Results
Royalty Pharma Reports Second Quarter 2025 Results Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $364 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $3,050 to $3,150 million NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “We delivered excellent second quarter 2025 results, as the strength of our diversified portfolio drove 20% grow...
Royalty Pharma Declares Third Quarter 2025 Dividend
Royalty Pharma Declares Third Quarter 2025 Dividend NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators ...
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Comp...
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate governance following acquisition of its external manager NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and...
Royalty Pharma to Announce Second Quarter 2025 Financial Results on Au...
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at to obtain conference call information and to view the live webcast. A replay of the conferenc...
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements ...
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma’s unique ability to provide capital at scale to help leading companies achieve their strategic goalsDaraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy t...
Barnwell Announces Third Adjournment of 2025 Annual Meeting Due to Ned...
Barnwell Announces Third Adjournment of 2025 Annual Meeting Due to Ned Sherwood’s Continued Refusal to Submit Votes Solicited from Shareholders HONOLULU, June 18, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) (“Barnwell” or the “Company”) today announced that its 2025 Annual Meeting of Shareholders, which reconvened yesterday, has been adjourned to Wednesday, September 3, 2025. Shareholders of record at the close of business on July 21, 2025 are eligible to vote at the adjourned 2025 Annual Meeting. Shareholders are encouraged to vote on the WHITE proxy card FOR...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
LINC LINCOLN EDUCATIONAL SERVICES
IMAX IMAX CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
PATK PATRICK INDUSTRIES INC.
MEG. MEG ENERGY CORP.
HRTG HERITAGE INSURANCE HOLDINGS INC.
ELF E.L.F. BEAUTY INC.
PAYS PAYSIGN INC
RPRX ROYALTY PHARMA PLC CLASS A
IMTX IMMATICS N V (A)
CVAC CUREVAC NV
IHS IHS HLDG LTD
SGHC SUPER GROUP (SGHC) LIMITED
CMPO COMPOSECURE INC
FTREV FORTREA HOLDINGS INC.
SGMT SAGIMET BIOSCIENCES INC
PC PREMIUM CATERING HOLDINGS LIMITED
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Heal...
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funde...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.